U.S. License Holder:
Bristol Myers Squibb
Date of License:
EMPLICITI (elotuzumab) is a SLAMF7-directed immunostimulatory antibody indicated in:
Combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies;
Combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.